Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Acta Pharmacologica Sinica Trial Scorecard: REDEFINE 1 and 2 CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide 3mg, Semaglutide 3mg Blend (SALE!) Polaris Peptides